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Summary 
Pertuzumab (Omnitarg! , 2C4) is a recombinant humanized monoclonal antibody targeted to extracellular region 
of HER-2. Previous results proved the inhibitory effect of Pertuzumab on the survival of breast cancer cells via 
MAPK and Akt pathway. Focal adhesion kinase (FAK) regulates multiple cellular processes including growth, 
differentiation, adhesion, motility and apoptosis. Here, we aimed to investigate the effects of Pertuzumab on ligand 
activated total FAK expression and phosphorylation in the HER-2 overexpressing BT-474 breast cancer cell line. 
Heregulin was used for ligand activation. We have found that FAK expression and phosphorylation were inhibited 




The HER-2 (c-erbB-2, neu) gene encodes a 185-kDa 
transmembrane glycoprotein that is a member of the 
epidermal growth factor receptor (EGFR or erbB) family 
of receptor tyrosine kinases. HER-2 mediates signal 
transduction, resulting in mitogenesis, apoptosis, 
angiogenesis, and cell differentiation (Ménard et al, 2000). 
The HER-2 gene is amplified and overexpressed in 20-
30% of invasive breast carcinomas, and is associated with 
increased metastatic potential and decreased overall 
survival (Slamon et al, 1987; Ménard et al, 2000). 
Pertuzumab (Omnitarg!, 2C4; Genentech) is a 
humanized monoclonal antibody against the dimerization 
domain of HER-2. This agent is the first in a new class of 
targeted therapeutics known as HER-2 ‘’dimerization 
inhibitors’’ (Franklin et al, 2004). In contrast to 
Trastuzumab, Pertuzumab sterically blocks HER-2 
dimerization with other HER receptors and blocks ligand-
activated signaling from HER-2/HER-1 and HER-2/HER-
3 heterodimers (Agus et al, 2002). It has been shown that 
the signaling pathways and cellular processes associated 
with tumor growth and progression could be inhibited with 
Pertuzumab both in vitro or in vivo models (Agus et al, 
2002). Pertuzumab has undergone phase I trials in patients 
with advanced solid malignancies (Agus et al, 2005; 
Albanell et al, 2008) and is currently in phase II clinical 
trials in NSCLC, metastatic breast, ovarian, and prostate 
cancers (Friess et al, 2005). 
The invasion and metastasis of cancer is the process 
that includes changes in cell adhesion and motility that 
tumor cells gain the ability to invade and migrate through 
the extracellular matrix. FAK is a tyrosine kinase 
considered to be a central molecule in integrin mediated 
signaling, and it is involved in cellular motility and 
protection against apoptosis (Parsons et al, 2000). 
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The aim of the present study was to assess the effects 
of Pertuzumab on the expression and tyrosine 
phosphorylation of FAK in HER-2 overexpressing BT-474 
breast cancer cells. 
 
II. Materials and Methods 
A. Materials 
Pertuzumab (Genentech) was provided in freezed dried 
powder at 50 mg. Heregulin -! and. Calnexin were purchased 
from Sigma and the anti-Human FAK antibody (M135) was 
purchased from TaKaRa laboratories. Anti-phospho FAK (pY397) 
antibody was purchased from Invitrogen. Horseradish 
peroxidase-conjugated anti-mouse and anti-rabbit antibodies 
were obtained from Sigma (USA). 
 
B. Cell culture 
BT-474 breast cancer cells were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA) and 
were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal calf serum, 1 mM 
glutamine, 10U/ml penicillin G and 10ug/ml streptomycin at 
37oC in 5% CO2-containing atmosphere. 
 
C. Immunohistochemistry 
BT-474 cells were plated in 6 well-plates (150.000 
cells/well) on coverslips one day before the experiment. After 24 
hrs, cells were treated with 10ng/ml Heregulin to induce HER-2/ 
HER-3 or HER-4 dimerization in the cells. Heregulin 
concentration was used as previously described (Gregory et al, 
2005). One and 10 mg/ml of Pertuzumab was added to wells and 
incubated for 2 to 24 hours. Each experiment was performed in 
triplicate and repeated three times. After 2 and 24 hours of 
incubation with Pertuzumab cells were fixed with 4% 
paraformaldehyde for 20 mins at room temperature and 
permeabilized with Sodium citrate for 5 mins at 4°C. Blocking 
was done with 10% bovine serum albumin (BSA) for 30 mins. 
And the cells were incubated with FAK (p125) antibody. HRP 
conjugated streptavidin was used in order to visualize the signal 
of the protein. The signal was developed with a substrate DAB 
(DAKO). Finally counterstaining was performed by 
hematoxylene staining. 
The positive staining of the Heregulin treated HER-2 
overexpressing BT-474 cells served as the positive internal 
control of the experiment. FAK-positive cells were counted in 
each slide and the ratio of the positive cells to the whole cell 
count was calculated as percentage. Minimum ten areas were 
counted from each triplicate slides and the standard deviations 
were calculated from the mean of the counts. If more than 20% 
of carcinoma cells were stained more intensely than that of 
untreated cells the sample was classified as strong FAK 
overexpression (3+) (Langer et al, 2004; Zinner et al, 2004; Krug 
et al, 2005). When the FAK immunostaining was equal 
compared to that of control, the sample was classified as 
intermediate expression (2+). When the FAK immunostaining 
was weaker than that of internal control, the cells were classified 
as low FAK expression (+1). The lack of FAK immunostaining 
was classified as negative (0). 
 
D. Immunoblotting 
BT-474 cells were treated with 10 ng/ml Heregulin and at 
the same time 1 and 10 µg/ml pertuzumab was added onto the 
cells. Cells were harvested using lysis buffer (10mM Tris-Cl, pH 
7.6, 5mM EDTA, 50mM NaCl, 30mM Na-pyrophosphate, 
50mM NaF, 100"M Na-ortovanadate, 1% Triton X and 1mM 
PMSF). Equal amounts of protein extracts were loaded in 8% 
SDS-polyacrylamide gel and transferred onto polyvinylidene 
difluoride (PVDF) membrane. Total FAK (p125) and Phospho-
FAK protein (pY397) were detected by rabbit anti-human FAK 
(TaKaRa) and anti-human phospho-FAK (Invitrogen) polyclonal 
antibodies and were used at a 1:1000 dilution in 4% BSA in 
PBS-Tween-20. Horseradish peroxidase-conjugated anti-rabbit 
antibody was obtained from Sigma (USA) and was detected 
using enhanced chemiluminescence (Amersham-Pharmacia 
Biotech, Piscataway, NJ). 
 
III. Results 
A. Immunohistochemical analysis of FAK 
Figure 1A shows the basal FAK phosphorylation without 
ligand activation in Her-2 overexpressed BT-474 cell line 
(+2). HER-2 dimerization with HER-3 or HER-4 was 
induced with 10 ng/ml Heregulin for 2 hours in BT-474 
cell line which is used as an internal positive control of the 
experiment (Figure 1B). FAK immunostaining revealed 
strong membranous and cytoplasmic staining with 10 
ng/ml of Heregulin treatment for 2 hours in BT-474 cells 
compared to control cells (+3). Figures 1C and 1D show 
FAK expression in BT-474 cells with 1"g/ml and 10"g/ml 
Pertuzumab in the presence of 10 ng/ml Heregulin for 2 
hours, respectively. The FAK expression was gradually 
decreased with the increasing amount of Pertuzumab at a 
concentration of 1 µg/ml and 10 µg/ml after 2 hours (+1). 
Figure 2A shows the basal FAK phosphorylation in BT-
474 cells without Heregulin for 24 hours. Her-2 
dimerization was activated with 10ng/ml Heregulin for 24 
hours in BT-474 cell line (Figure 2B).Figures 2C and 2D 
show decrement of FAK expression with either 1"g/ml or 
10"g/ml Pertuzumab in the presence of 10 ng/ml 
Heregulin for 24 hours in BT-474 cell line. The cells in 
each condition were seeded triplicate and counted from 
minumum 10 areas of the slides and the ratio of positive 
cells to whole cell count of three experiments was 
calculated as percentage. Figure 3 shows the mean value 
of three experiments ± SD. The decrease of FAK 
expression was not significant in the cells treated with 
1"g/ml and 10 "g/ml Pertuzumab in the presence of 
10ng/ml Heregulin for 2 hours when compared to the ones 
treated only with Heregulin (p>0.05). However, a 
significant decrease was present in the FAK expression in 
the cells treated with 1"g/ml and 10"g/ml Pertuzumab for 
24 hours compared to treatment with 10 ng/ml Heregulin 
alone for 24 hours (p=0.04 and p=0.005, respectively). 
 
B. Evaluation of expression and 
phosphorylation of the FAK with 
immunoblotting 
We further confirmed our immunostaining results 
with immunoblotting. FAK expression was gradually 
decreased with the increasing amount of Pertuzumab at a 
concentration of 1"g/ml and 10"g/ml either in 2 or in 24 
hours (Figure 4). We also investigated whether 
Pertuzumab could modulate protein phosphorylation of the 
signal transduction molecule- the FAK. FAK 
phosphorylation was strikingly inhibited with Pertuzumab 
in dose-dependent manner after 24 hours. Figure 5 shows 
the decrement of FAK phosphorylation in response to 
Pertuzumab in BT-474 breast cancer cells. 





Figure 1. Expression of FAK in BT-474 cells for 2 hours. (A) Basal FAK expressionwithout HER-2 dimerization (B) with 10ng/ml of 




Figure 2. Expression of FAK in BT-474 cells for 24 hours. (A) Basal FAK expression without HER-2 dimerization (B) with 10ng/ml 
of Heregulin (C) with 1µg/ml Pertuzumab + 10ng/ml Heregulin (D) with 10µg/ml Pertuzumab + 10ng/ml Heregulin. 




Figure-3. Pertuzumab inhibits FAK expression with immunostaing. Each immunostaining experiment was done in triplicates. The 
cells were counted and the ratio of positive cells to whole cell count was calculated as percentage. Minimum 10 areas from each slide 
were counted. The standart deviations were calculated according to the whole cell count. The decrease of the FAK expression is 
significant in the cells treated with 10 µg/ml Pertuzumab for 24 hours when compared to the ones treated with 10ng/ml Heregulin for 24 
hours (p=0.005). Likewise a significant decrease is present in the FAK expression in the cells treated with 1 µg/ml Pertuzumab for 24 
hours (p=0.04). Decrease in FAK expression was not significant in the cells treated with 1 µg/ml and 10 µg/ml 2C4 in the presence of 




Figure 4. Pertuzumab decreases 
the expression of FAK with 
immunoblotting.The BT-474 
cells were treated with 1 µg/ml 
and 10 µg/ml of Pertuzumab in the 
presence of 10ng/ml Heregulin for 
2 and 24 hours. The inhibitory 
effect of Pertuzumab on FAK 
expression was observed in the 
cells treated with 10 µg/ml of 
Pertuzumab for 24 hours. The 
equal loading was adjusted with 






Figure 5. Pertuzumab decreases the phosphorylation of FAK. The BT-474 cells were treated with 10ng/ml of Heregulin for 2 and 24 
hours. Meanwhile they were treated with 1 µg/ml and 10 µg/ml of Pertuzumab. The inhibitory effect of Pertuzumab on phosphorylated-
FAK was observed in the cells treated with 10 µg/ml of Pertuzumab for 24 hours. The equal loading was adjusted with calnexin 
according to the Comassie blue staining. 
 




In this report, for the first time we have shown that 
Heregulin activated total FAK expression and FAK 
phosphorylation were inhibited with Pertuzumab in BT-
474 HER-2 overexpressing breast cancer cell line. 
Even though the surgical techniques and the adjuvant 
therapies have been proven to be useful in the treatment of 
primary tumors (Entschladen et al, 2004), invasion and 
metastasis remain a major cause of poor prognosis and 
death in cancer patients. Trastuzumab monotherapy offers 
clinical benefit to a subset of HER-2-overexpressing 
metastatic breast cancers. However, the majority of breast 
cancers that initially respond to Trastuzumab-containing 
regimens begin to progress again within 1 year (Albanell 
and Baselga, 2001). The recombinant humanized HER-2 
monoclonal antibody Pertuzumab sterically blocks 
dimerization of HER-2 with other HER receptors (Agus et 
al, 2002) known as ‘’HER dimerization inhibitors’’. 
Reports from phase I and II trials indicate that Pertuzumab 
plays an important role in the inhibition of the solid 
tumors progression including breast cancer (Parsons et al, 
2000; Friess et al, 2005; Albanell et al, 2008). Beside these 
reports, which ligand activated HER-2 signaling molecules 
inhibited by Pertuzumab are not completely detected. 
Signaling pathways activated by HER-2 include the 
phosphatidylinositol 3-kinase (PI3K)/Akt and MAPK 
cascades (Mendoza et al, 2002; Nahta et al, 2004). The 
reports of studies on the effects of Pertuzumab show that 
inhibiting the survival of breast cancer cells via MAPK 
(Agus et al, 2002) and Akt pathway (Nahta et al, 2004). 
The combination of Trastuzumab and 2C4 reduced the 
serine phosphorylation of Akt whereas signaling from the 
MAPK cascade was not inhibited (Nahta et al, 2004). 
Previous studies also show that Pertuzumab inhibited 
Heregulin-activated mitogenic signaling in breast and 
prostate cancer models in vitro and in vivo because of 
dissociation of HER-2/HER-3 dimers (Agus et al, 2002; 
Mendoza et al, 2002). 
FAK is a cytoplasmic tyrosine kinase that plays an 
important role in integrin-mediated signal transduction 
pathways closely related to cell adhesion, motility, and 
growth (Parsons et al, 2000; Parsons et al, 2000; 
Schlaepfer et al, 2004). Upregulation of FAK expression is 
associated with oncogenesis (Cance et al, 2000) and 
decrease in FAK is associated with the loss of ability to 
attach (Mitra et al, 2005), decreased migration (Schlaepfer 
et al, 2004) and induction of apoptosis (Parsons, 2003). In 
our study, the FAK expression and phosphorylation were 
increased in response to HER-2 dimerization induced by 
Heregulin. Specifically, FAK is phosphorylated at 
multiple sites in cells stimulated by mitogenic agonists 
that act via heptahelical GPCRs including bombesin 
(Zachary et al, 1992; Salazar and Rozengurt, 2001) and 
lysophosphatidic acid (Seufferlein and Rozengurt, 1995), 
ligands of tyrosine kinase receptors, including EGF 
(Leventhal et al, 1997; Ojaniemi and Vuori, 1997), 
integrin clustering induced by cell adhesion (Owen et al, 
1999; Ruest et al, 2000) and activated variants of pp60src 
(Guan and Shalloway, 1992; Parsons and Parsons, 1997). 
It is increasingly recognized that FAK functions as a point 
of convergence and integration in the action of multiple 
signals (Rozengurt, 1995). In recent studies, Vadlamudi 
and colleagues utilized human breast cancer cell lines in 
vitro to establish a novel signaling pathway involving 
HER-2, phospho-Src Tyr-215 and phospho-FAK Tyr-861 
leading to increased cellular motility (Vadlamudi et al, 
2002, 2003). The authors showed that heregulin-induced 
HER-2 activation resulted in phosphorylation of FAK at 
tyrosine 861. Further support to our study was reported by 
Schmitz et al. They have reported that HER-2 and FAK 
associated signaling in tumor tissue of breast cancer 
patients (Schmitz et al, 2005). A recent study also 
identified frequent polysomic patterns for chromosome 1, 
chromosome 8 and chromosome 17 that are indicative for 
increased tumor malignancy in breast cancer (Nakopoulou 
et al, 2002). The FAK is located on chromosome 8 and the 
HER-2 is located on chromosome 17. These polysomic 
patterns can be lead to the alterations in HER-2 and FAK 
expression and signaling in breast cancer. 
In the present study, a significant downregulation of 
FAK expression and phosphorylation with Pertuzumab 
was observed, suggesting that Pertuzumab may serve as a 
potential important anticancer agent for breast cancer. 
Increased FAK expression and phosphorylation by ligand 
activated HER-2 signaling and inhibition with Pertuzumab 
indicating that FAK also could be an important 
pharmacologic target site and whether FAK is the 
upstream molecule of MAPK/Akt pathway of apoptosis 
and/or metastasis remains to be investigated. 
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